Analytical Data
-
Gene name
MYC
- Application
-
Alternative Names
MYC；BHLHE39；Myc proto-oncogene Protein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01106-2
-
Expression Region
1-454aa
-
AA Sequence
MDFFRVVENQQPPATMPLNVSFTNRNYDLDYDSVQPYFYCDEEENFYQQQ QQSELQPPAPSEDIWKKFELLPTPPLSPSRRSGLCSPSYVAVTPFSLRGD NDGGGGSFSTADQLEMVTELLGGDMVNQSFICDPDDETFIKNIIIQDCMW SGFSAAAKLVSEKLASYQAARKDSGSPNPARGHSVCSTSSLYLQDLSAAA SECIDPSVVFPYPLNDSSSPKSCASQDSSAFSPSSDSLLSSTESSPQGSP EPLVLHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGKRSESGSPSAG GHSKPPHSPLVLKRCHVSTHQHNYAAPPSTRKDYPAAKRVKLDSVRVLRQ ISNNRKCTSPRSSDTEENVKRRTHNVLERQRRNELKRSFFALRDQIPELE NNEKAPKVVILKKATAYILSVQAEEQKLISEEDLLRKRREQLKHKLEQLR NSCAESGGGGSPGRRRRRRRRRRR
-
Molecular Weight
53 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The MYC protein, a crucial transcription factor, plays a significant role in regulating cell proliferation, growth, and metabolism. Aberrant expression of MYC is frequently associated with various types of cancers, making it a focal point for oncogenetic research. Historically, MYC was first identified in the context of the Burkitt lymphoma, and since then, its implications have expanded to encompass a wide range of malignancies, including breast, colon, and lung cancers. The MYC protein functions by binding to DNA and modulating gene expression, influencing processes such as cellular survival and apoptosis. Given its pivotal role in cancer biology, the study of MYC and its signaling pathways has garnered considerable attention, leading to the exploration of MYC as a therapeutic target. Researchers have been investigating the development of MYC inhibitors and recombinant MYC proteins to better understand its functionality and interaction with various cellular components. Furthermore, the production of recombinant MYC proteins allows for detailed biochemical characterization, which can elucidate its regulatory mechanisms and inform the design of targeted therapies. As such, the focus on recombinant MYC proteins not only enhances our comprehension of MYC's role in cancer but also paves the way for innovative strategies aimed at modulating its activity for therapeutic benefits in oncology.
